PO.PS01.08 · 人群科学
跨地理区域的食管及胃食管交界处腺癌中的突变过程
Mutational processes in esophageal and gastroesophageal junction adenocarcinomas across geographical regions
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
食管腺癌(EAC)和胃食管交界处癌(GEJ)共享多种危险因素,如反流性疾病、肥胖和吸烟。尽管它们解剖位置相邻且病因重叠,但常分别被视为食管肿瘤和胃肿瘤。本研究旨在解析在EAC和GEJ癌症发生过程中起作用的突变过程,并确定这些过程是否在不同肿瘤部位和地理区域间共享。
研究从来自八个国家(中国、伊朗、英国、加拿大、肯尼亚、马拉维、巴西和哥伦比亚)的520例EAC/GEJ病例(159例EAC和361例GEJ)生成了全基因组测序数据,并具有可用的人口学、生活方式和环境暴露数据。使用SigProfilerExtractor提取突变特征并分解为参考特征。使用多变量回归模型评估突变特征与流行病学或分子特征之间的关联。
我们的分析揭示出17个来自COSMIC目录的参考特征,以及既往癌症数据集中描述的三个特征。EAC/GEJ肿瘤表现出与胃酸反流相关的SBS17a和SBS17b的高负荷,占中位特征负荷的26.8%。SBS-D特征被推测由DNA修复的不忠实性引起,是第二丰富的特征(中位相对负荷12%),提示其在EAC/GEJ致癌过程中具有相关作用。EAC和GEJ癌症共享高度相似的突变、驱动基因和拷贝数图谱,指向共享的诱变过程,唯一例外是SBS-D,其在食管下段和远端的癌症中富集。SBS17a/b特征与肥胖呈正相关(p值<0.0005),尤其在EAC病例中,支持了肥胖可能加剧反流性疾病的流行病学观点。我们未观察到特征负荷与其他危险因素(如烟草)的差异,提示烟草在此类癌症中的致癌作用可能是促进性而非诱变性的。最后,我们发现年龄标准化发病率与SBS5、SBS8和SBS-D特征之间存在关联,提示高风险人群中内源性细胞功能可能存在失调。
本研究阐明了驱动GEJ/EAC癌症的突变力量。我们的结果显示,各组织间整体上共享突变图谱,并提示肥胖增强了反流相关诱变的存在。所观察到的各国间差异可提供相关信息,以助力全球预防策略的制定。
查看英文原文 English abstract
Esophageal adenocarcinomas (EAC) and gastroesophageal junction cancers (GEJ) share multiple risk factors such as reflux disease, obesity, and tobacco smoking. Despite their anatomical proximity and overlapping etiology, they are often considered as esophageal and gastric tumors, respectively. This study aims to decipher the mutational processes that have been operative in EAC and GEJ cancer development and determine whether these are shared across tumor sites and geographical regions.
Whole-genome sequencing data were generated from 520 EAC/GEJ cases (159 EAC and 361 GEJ) from eight countries (China, Iran, United Kingdom, Canada, Kenya, Malawi, Brazil, and Colombia), with available demographic, lifestyle, and environmental exposure data. Mutational signatures were extracted using SigProfilerExtractor and decomposed into reference signatures. Associations between the mutational signatures and epidemiological or molecular features were assessed using multivariate regression models.
Our analysis revealed 17 reference signatures from the COSMIC catalogue, and three signatures described in previous cancer datasets. EAC/GEJ tumors exhibited high burdens of SBS17a and SBS17b, linked to acid reflux, accounting for 26.8% of the median signature burdens. Signature SBS-D, which has been speculated to be caused by DNA repair infidelity, was the second most abundant signature (12% median relative burden), suggesting a relevant role in EAC/GEJ carcinogenesis. EAC and GEJ cancers shared a highly similar mutation, driver, and copy number profile, pointing to shared mutagenic processes, with the exception of SBS-D, which showed enrichment in cancers from the lower and distal esophagus. Signatures SBS17a/b were positively associated with obesity (p-value<0.0005), particularly in EAC cases, supporting the epidemiological notion that obesity may exacerbate reflux disease. We observed no differences in signature burdens with other risk factors, such as tobacco, suggesting its carcinogenic effect in this cancer type could be promotional rather than mutagenic. Finally, we found an association between age-standardized incidence and the signatures SBS5, SBS8, and SBS-D, suggesting a potential dysregulation of endogenous cellular functions in high-risk populations.
This study delineates the mutational forces driving GEJ/EAC cancers. Our results show an overall shared mutational profile across tissues and suggest that obesity enhances the presence of reflux-related mutagenesis. The observed differences across countries could provide relevant information to aid in the development of global prevention strategies.
利益披露 Disclosure
L. Torrens, None..
S. Moody, None..
J. Pang, None..
B. Abedi-Ardekani, None..
A. Noorani, None..
H. Zhang, None..
P. Gallego-Garcia, None..
V. Gaborieau, None..
T. Cattiaux, None..
P. Chopard, None..
S. Fitzgerald, None..
C. Latimer, None..
C. Carreira, None..
M. Diaz-Gay, None..
L. Humphreys, None.
L. B. Alexandrov,
io9 co-founder, chief scientific officer, scientific advisory member and consultant.
Inocras scientific advisory board.
M. R. Stratton,
Quotient Therapeutics founder, consultant, and stockholder.
S. Perdomo, None..
P. Brennan, None.